| Aug 5 |
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
|
| Aug 1 |
Why Ocugen (OCGN) Stock Is Falling
|
| Aug 1 |
Ocugen dips 11%, issues $35M stock at $1.15 per share
|
| Aug 1 |
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
|
| Jul 31 |
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
|
| Jul 29 |
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
|
| Jul 25 |
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
|
| Jul 11 |
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
|
| Jul 6 |
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
|
| Jul 1 |
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
|
